Syntal Capital Partners’s Amedisys AMED Stock Holding History

Syntal Capital Partners’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,109	Closed	-$1.44M	–	107
2020 Q3	$1.44M	Buy	+6,109	New	+$1.39M	0.65%	46

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Syntal Capital Partners's AMED Position: Q4 2020 in Review

Syntal Capital Partners sold out of Amedisys (AMED) in Q4 2020, closing a stake of 6,109 shares — an estimated $1.44M sold.

Syntal Capital Partners first reported a position in AMED in Q3 2020 and held it in 1 quarter. The position peaked at $1.44M in Q3 2020. 396 funds tracked by Wall St. Rank hold AMED as of Q4 2020.

Syntal Capital Partners reported no remaining Amedisys position as of Q4 2020 after selling out during the quarter.
Syntal Capital Partners sold 6,109 Amedisys shares in Q4 2020, an estimated $1.44M.
Syntal Capital Partners first reported a position in Amedisys in Q3 2020 and held it in 1 quarter.
Syntal Capital Partners's Amedisys position peaked at $1.44M in Q3 2020.
396 funds tracked by Wall St. Rank held Amedisys as of Q4 2020.

Based on Syntal Capital Partners's 13F filing for Q4 2020, filed 11 Feb 2021.